Is NCT07006506 recruiting in New York, NY?

Yes, NCT07006506 is currently recruiting participants at its New York, NY location. This graft-versus-host disease clinical trial is actively enrolling qualified participants.

How do I join the graft-versus-host disease clinical trial in New York?

To join this clinical trial in New York, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this New York clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Graft-Versus-Host Disease Clinical Trial in New York, NY

About This Graft-Versus-Host Disease Study in New York

The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Patients ≥ 18 years-old at time of consent.

Diagnosis: hematologic malignancy in morphologic remission who will be treated with RI or NMA conditioning and GVHD prophylaxis CNI-based (CNI without PTCY) plus abatacept or PTCY-based (CNI with PTCY).

Recipients of 7-8/8 related or unrelated HLA-matched or related haploidentical donor.

Peripheral blood stem cell graft

Allo-HCT day \<120 at time of consent Post-HCT inclusion criteria (within 3 weeks before start of belumosudil treatment)

Patient has received an allo-HCT transplant and is in morphologic remission (blasts \<5%, no evidence of extramedullary disease in AML or MDS). Patients with CR with incomplete count recovery (CRp or CRi) or minimal residual disease are allowed.

Patient has achieved engraftment. Engraftment is defined as ANC≥500/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day apart). The patient must not have had a platelet transfusion within 7 days before the first measurement.

Patient is ≥ 80 days and ≤ 20 days from allo-HCT infusion.

Karnofsky score ≥ 70%.

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit of normal (ULN)

Total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia).

Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2

Female subjects of childbearing potential (≤ 50 years old) have a negative serum or urine pregnancy test. Females of childbearing potential are defined as females without prior hysterectomy or who have had any evidence of menses in the past 12 months. ° Sexually active females of childbearing potential enrolled in the study must agree to consistently use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes: \

Intrauterine device (IUD) plus one barrier method \

Stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus one barrier method \

2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm); or \

A vasectomized partner

For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug.

Exclusion Criteria

Recipient of CD34+ selected or engineered stem cell graft.

Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin).

Evidence of current uncontrolled cardiovascular conditions, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.

Pulmonary dysfunction with DLCO \<50% corrected for hemoglobin

Patients with an active secondary malignancy or prior malignancy requiring systemic therapy within the past 5 years. Exceptions include adequately treated localized non melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma), as well as localized prostate cancer considered low risk and stable under treatment or surveillance. Post-HCT exclusion criteria

Uncontrolled infection, including active hepatitis B and C. Definitive therapy for infection is required and must have no signs of progression within 7 days of the first day of study drug treatment.

Use of investigational agent within 14 days pre-HCT or anytime thereafter.

Active acute or chronic GVHD requiring systemic therapy (topical or local therapies are allowed).

Active treatment with corticosteroids at a dose of ≥ 0.25 mg/kg/day for non-GVHD indication.

Uncontrolled psychosis, active suicidal ideation, or psychiatric hospitalization within the past year

Female patient who is pregnant or breastfeeding.

Prior therapy with belumosudil.

Known allergy or sensitivity to belumosudil or any other ROCK2 inhibitor.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07006506) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Graft-Versus-Host Disease Treatment Options in New York, NY

If you're searching for graft-versus-host disease treatment options in New York, NY, this clinical trial (NCT07006506) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced graft-versus-host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all graft-versus-host disease clinical trials near you to find additional studies recruiting in your area.

Graft-Versus-Host Disease Clinical Trial in New York, NY

Expert Care in New York

IRB Approved

No-Cost Care

Apply for This New York Location

Why Participate?

Simple Process